Omeros, a Seattle-based biopharmaceutical company with 198 employees, focuses on developing therapeutics for immunologic disorders and is advancing several candidates, including narsoplimab and OMS527, in clinical trials. The company went public on October 8, 2009.
Based on our analysis, Omeros has received an overvalued rating of 1 out of 5 stars from Cashu, primarily due to a few concerning financial metrics.
One of the key issues is the company's net profit margin, which stands at -187.13%. This ratio indicates that Omeros is not only unprofitable but is losing a significant portion of its revenue, worse than the sector average of -138.75%. A negative net profit margin suggests ongoing operational challenges and raises concerns about the company's ability to generate sustainable profits in the future.
Additionally, the return on assets (ROA) ratio for Omeros is -31.15%, which is also worse than the sector's ROA of -47.85%. The ROA measures how effectively a company is using its assets to generate earnings. In this case, Omeros is struggling to leverage its assets efficiently, which could hinder growth potential.
Lastly, the company’s return on equity (ROE) is at 55.34%, significantly better than the sector's -74.35%. However, this high ROE is not enough to offset the other negative metrics, especially since it reflects how well the company is generating profit from shareholders' equity but does not indicate overall financial health.
In summary, Omeros is facing significant challenges reflected in its negative profit margin and return on assets, leading to its overvalued rating.
This is not a comprehensive overview of our valuation, and should not be viewed as financial advice. Always do your own research before considering an investment.
📡️ Health Care
Overvalued
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.